尤瑞克林治疗急性进展性脑梗死临床疗效观察

The effect of Urinary Kallidinogenase on acute progressive cerebral infarction

目的 观察尤瑞克林对急性进展性脑梗死的临床疗效.方法 80例进展性脑梗死患者分成治疗组及对照组,两组患者的年龄、性别、用药前神经功能缺损评分、梗死部位、伴发疾病等经统计学处理差异均无显著性.治疗组和对照组常规给予抗血小板聚集治疗,治疗组加用尤瑞克林,两组减轻脑水肿、控制血压、控制血糖、调节血脂、维持水电解质平衡、抗感染等治疗措施均相似.根据美国国立卒中量表（NIHSS）记录两组治疗前和治疗后神经功能缺损程度,观察用药14d后神经功能缺损变化,监测用药期间不良反应,用药结束后进行统计学分析.结果 两组治疗后较治疗前NIHSS均有改善,与治疗前比较有统计学差异（P＜0.05）.与对照组相比,尤瑞克林组治疗的NIHSS评分改善更显著（P＜0.05）.治疗组总有效率为87.5%,对照组总有效率为67.5%,两组间差异有显著性（P＜0.05）.未见不良反应.结论 尤瑞克林对进展性脑梗死有较好的疗效,可作为治疗进展性脑梗死的一个新的参考选择.

Objective To investigate the effect of Urinary Kallidinogenase on acute progressive cerebral infarction. Methods Eighty patients with acute progressive cerebral infarction were randomly divided into two groups： treatment group （n = 40） and control group（ n = 40）. According to Chinese Guidelines for Prevention and Management Cerebrovascular Disease, two groups were treated with basic therapies, including Anti-platelet aggregation, neurologic protection, blood pressure control, and rehabilitation. In addition, treatment group was administrated intravenous injection of Urinary Kallidinogenase 0.15PNA per day for 14 days. NIHSS （the National Institutes of Health stroke scale） score was compared before and after the treatment. Results The study showed that, after the treatment, the NIHSS score was lower than that before treatment in each group （P 〈 0.05）. Compared with control group, the reduction of NIHSS score was more significant in the treatment group （P 〈 0.05）. The total efficacy was 87.50% in the treatment group and 67.5% in the control group, with a significant difference between the two groups （P 〈 0.05）. No obvious side-effect was found in the treatment group. Conclusions Urinary Kallidinogenase is effective and safe in the treatment of acute progressive cerebral infarction.